ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,841 to 4,860 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Dapagliflozin 10mg vs Placebo: deaths from any cause41 of 625

54 of 625

-2.1 points

-5.1 to 0.9

1,250NCT04350593

Dapagliflozin in Respiratory Failure in Patients With COVID-19

Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization or Death2 of 628

2 of 622

-0.0 points

-0.9 to 0.9

1,250NCT05894577

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization, Urgent Care, Emergency Room Visit, or Death18 of 628

18 of 622

-0.0 points

-2.0 to 1.9

1,250NCT05894577

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Arm F - Montelukast vs Arm F - Placebo: serious adverse events6 of 628

3 of 622

0.5 points

-0.6 to 1.6

1,250NCT05894577

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Leg/Foot Swelling as a Side Effect of Antihypertensive Medication at Six Months247 of 656

208 of 593

2.6 points

-2.8 to 7.9

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting High Confidence in Measuring BP at Home at Six Months376 of 652

412 of 597

-11.3 points

-16.6 to -6.0

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Tiredness as a Side Effect of Antihypertensive Medication at Six Months437 of 656

376 of 593

3.2 points

-2.1 to 8.5

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Cough as a Side Effect of Antihypertensive Medications at Six Months202 of 656

212 of 593

-5.0 points

-10.2 to 0.3

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Sexual Symptoms as a Side Effect of Antihypertensive Medication at Six Months174 of 656

132 of 593

4.3 points

-0.5 to 9.0

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Frequent Urination as a Side Effect of Antihypertensive Medication at Six Months331 of 656

293 of 593

1.0 points

-4.5 to 6.6

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Best Practice Clinic-Based Care vs Telehealth Care: Number of Participants Reporting Dizziness as a Side Effect of Antihypertensive Medication at Six Months247 of 656

232 of 593

-1.5 points

-6.9 to 3.9

1,249NCT02996565

Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure

Routine Collection of Patient-Reported Health Status (KCCQ-12 Arm) vs Usual Care: deaths from any cause23 of 624

21 of 624

0.3 points

-1.8 to 2.4

1,248NCT04164004

Patient-Reported Outcome Measurement in Heart Failure Clinic

Buprenorphine/Nx vs Methadone: serious adverse events38 of 727

45 of 520

-3.4 points

-6.5 to -0.6

1,247NCT00315341

Starting Treatment With Agonist Replacement Therapies (START)

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Rash, in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines.10 of 935

3 of 312

0.1 points

-1.8 to 1.2

1,247NCT00453986

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Serious Adverse Events (SAEs), in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines.7 of 935

1 of 312

0.4 points

-1.1 to 1.3

1,247NCT00453986

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Unsolicited Adverse Events (AEs), in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines.135 of 935

47 of 312

-0.6 points

-5.5 to 3.7

1,247NCT00453986

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Adverse Events (AEs) Resulting in Emergency Room (ER) Visits, in Subjects Receiving the Nimenrix (From the 3 Manufactured Lots Pooled) or the Mencevax ACWY Vaccines.13 of 935

1 of 312

1.1 points

-0.5 to 2.1

1,247NCT00453986

Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults

STRATIS vs Needle-Syringe: serious adverse events1 of 624

2 of 623

-0.2 points

-1.0 to 0.6

1,247NCT01688921

Jet Injection for Influenza

Daily Emollient vs Natural Skin: deaths from any cause1 of 614

1 of 633

0.0 points

-0.7 to 0.8

1,247NCT03409367

A Community-based Assessment of Skin Care, Allergies, and Eczema

Daily Emollient vs Natural Skin: serious adverse events25 of 614

39 of 633

-2.1 points

-4.6 to 0.4

1,247NCT03409367

A Community-based Assessment of Skin Care, Allergies, and Eczema

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=243"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=243

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT04350593-deaths",
        "title": "Dapagliflozin 10mg vs Placebo: deaths from any cause",
        "summary": "41 of 625 against 54 of 625; risk difference -2.1 points, 95% interval -5.1 to 0.9; NCT04350593, Dapagliflozin in Respiratory Failure in Patients With COVID-19",
        "record": "/library/comparisons/NCT04350593-deaths",
        "nct_id": "NCT04350593",
        "kind": "deaths",
        "participants": 1250,
        "risk_difference": {
          "value": -0.0208,
          "lower": -0.05065850743845549,
          "upper": 0.008788222285480565
        },
        "group_1": "41 of 625",
        "group_2": "54 of 625",
        "difference": "-2.1 points",
        "interval": "-5.1 to 0.9",
        "trial_title": "Dapagliflozin in Respiratory Failure in Patients With COVID-19"
      },
      {
        "id": "NCT05894577-722f18ed",
        "title": "Arm F - Montelukast vs Arm F - Placebo: Number of Participants With Hospitalization or Death",
        "summary": "2 of 628 against 2 of 622; risk difference -0.0 points, 95% interval -0.9 to 0.9; NCT05894577, ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)",
        "record": "/library/comparisons/NCT05894577-722f18ed",
        "nct_id": "NCT05894577",
        "kind": "outcome",
        "participants": 1250,
        "risk_difference": {
          "value": -0.00003072070780510763,
          "lower": -0.008773464999726624,
          "upper": 0.00864103183992847
        },
        "group_1": "2 of 628",
        "group_2": "2 of 622",
        "difference": "-0.0 points",
        "interval": "-0.9 to 0.9",
        "trial_title": "ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=244",
  "request_id": "nJy-zPE80axGES0G"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

Journal index

PubMed and NLM's journal list

One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?